Nano Bugle

A window into applied science supported by INL

Crystax Oryzon Acquires Biopharmaceutical Crystax

Image obtained from Crystax Pharmaceuticals S.L. web site

Image obtained from Crystax Pharmaceuticals S.L. web site

The spin-off from the Universidad de Barcelona and the CSIC, Oryzon, specialized in new biomarkers and therapeutic targets in oncology and neurodegenerative diseases, acquired the biopharmaceutical Crystax Pharmaceuticals S.L., which focuses in developing new therapeutic molecules in cancer.

Advertisements

June 23, 2009 - Posted by | Nanomedicine | ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: